Urokinase
- Generic Name
- Urokinase
- Brand Names
- Kinlytic
- Drug Type
- Biotech
- CAS Number
- 9039-53-6
- Unique Ingredient Identifier
- 83G67E21XI
- Background
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond.
Urokinase was granted FDA approval on 16 January 1978.
- Indication
In Canada, urokinase is indicated for lysis of acute massive pulmonary emboli, acute thrombi obstructing coronary arteries, occlusive thromboemboli in peripheral arteries and grafts, and restoration of patency to intravenous catheters.
- Associated Conditions
- Obstruction; Catheter, Infusion Catheter (Vascular), Pulmonary Embolism, Pulmonary Embolism Acute Massive, Thromboembolism of the Coronary Artery, Thromboembolism of the Graft, Thromboembolism of the Peripheral Artery
Comparison of Standard Versus High Dose Urokinase for Dysfunctional Tunneled Dialysis Catheters in Haemodialysis Patients: a Randomized Controlled Trial
- Conditions
- HemodialysisThrombolytic TherapyDialysis Access DysfunctionRandomised Controlled TrialEnd Stage Renal Disease (ESRD)
- Interventions
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- National Healthcare Group, Singapore
- Target Recruit Count
- 44
- Registration Number
- NCT06802679
- Locations
- 🇸🇬
Khoo Teck Puat Hospital, Singapore, Singapore
Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)
- Conditions
- Aneurysmal Subarachnoid Hemorrhage
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Second Affiliated Hospital of Nanchang University
- Target Recruit Count
- 424
- Registration Number
- NCT06284642
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Treatment of Acute Ischemic StroKe With Intravenous UroKinase Real-world Research: a Multicenter, Prospective Study
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 1800
- Registration Number
- NCT06194968
- Locations
- 🇨🇳
Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
🇨🇳Red Cross Hospital of Yulin City, Yulin, Guangxi, China
🇨🇳The First People's Hospital of Yulin, Yulin, Guangxi, China
Brain Aneurysms: Utility of Cisternal Urokinase Irrigation
- Conditions
- Subarachnoid Hemorrhage, AneurysmalVasospasm, CerebralHydrocephalus
- Interventions
- Procedure: Endovascular treatmentProcedure: External ventricular drainProcedure: Clipping
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- University of Valencia
- Target Recruit Count
- 247
- Registration Number
- NCT04792944
- Locations
- 🇪🇸
Hospital General Universitario de Valencia, Valencia, Spain
Thrombolysis of Urokinase for Minor Stroke
- Conditions
- Minor Stroke
- Interventions
- Drug: Aspirin;Clopidogrel
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 1005
- Registration Number
- NCT04420351
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- General Hospital of Shenyang Military Region
- Registration Number
- NCT03997292
- Locations
- 🇨🇳
General Hospital of Shenyang Military Region, Shenyang, Liaoning, China
Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial
- Conditions
- Acute Ischaemic Stroke
- Interventions
- Drug: rhPro-UK simulation agent
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 149
- Registration Number
- NCT03578822
- Locations
- 🇨🇳
XuanWu Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Harrison International Peace Hospital, Hengshui, Hebei, China
🇨🇳Tangshan Gongren Hospital, Tangshan, Hebei, China
Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)
- Conditions
- Acute Ischaemic Stroke
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 674
- Registration Number
- NCT03541668
- Locations
- 🇨🇳
XuanWu Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Beijing Luhe Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳The First Hospital of Handan, Handan, Hebei, China
Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- General Hospital of Shenyang Military Region
- Target Recruit Count
- 4000
- Registration Number
- NCT02854592
- Locations
- 🇨🇳
General Hospital of ShenYang Military Region, ShenYang, China
Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis
- Conditions
- Venous Thrombosis
- Interventions
- Device: a manual spiral thrombus broken suction deviceProcedure: catheter-directed thrombolysis
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Xuzhou Medical University
- Target Recruit Count
- 40
- Registration Number
- NCT02414802
- Locations
- 🇨🇳
Department of Interventional Radiology and Vascular Surgery, the Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.